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Autoimmunity: Another pathway towards arthritis
Rikard Holmdahl
A new pathway leading to arthritis has been revealed by
the discovery that antibodies specific for a ubiquitously
expressed antigen are able to transfer a severe arthritic
phenotype in mice. This new model will be useful for
further analyses of the different pathways involved in
rheumatoid arthritis.
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It is still unknown why peripheral joints are the primary
target in a variety of diseases that affect a large proportion
of the human population. For example, in osteoarthritis,
cartilaginous weight-bearing joints degenerate or are
destroyed by poorly understood inflammatory processes. In
a diverse group of diseases that affect joint capsules, such as
psoriasis arthritis and ankylosing spondylitis, inflammatory
and regenerative responses lead to pathological processes
in the insertion areas of tendons, joint deformities and/or
fusions. In rheumatoid arthritis, peripheral diarthrodial car-
tilaginous joints, for example joints in hands and feet, are
attacked by an erosive inflammatory process leading to
joint destruction and chronic disability. From an evolution-
ary standpoint, it would seem important to have intact and
non-diseased joints but, in reality, these parts of the body
seem to be particularly afflicted by disease. Why is this so? 
Joints are vulnerable to trauma by their very nature. In
particular, today’s environment forces us to use our joints
in a different way from that which has been genetically
selected and this could induce degeneration or deforma-
tions of the joints. Also, macrophages are present in joints
and these cells function both in a systemic manner to
phagocytose circulating infectious pathogens or debris and
in a localised manner to clear the joints of scavenged
debris derived from cartilage. This defence system could
overreact, leading to autoreactivity, or react unsuitably,
resulting in the persistence of pathogens. Finally, joints
contain cartilage, which is not vascularized or drained by
lymphatic vessels. These areas may therefore contain pro-
teins that have not been fully exposed to the immune
system and could lead to autoimmune inflammatory
destruction of the joints. 
All of the above factors influence the various joint dis-
eases, but to different degrees in each case. Rheumatoid
arthritis is believed to be caused by a disturbance in the
normal interactions between the immune system and the
defence system within the joints. This disruption results
in the transformation of the macrophages and inflamma-
tory cells in the synovial fluid surrounding the joints to
form a so-called pannus tissue that erodes the joints. The
likelihood that new inflammatory phenomena or factors
will be detected in rheumatoid arthritis is high because
most inflammatory pathways seem to operate in this
disease. Thus, although rheumatoid arthritis is defined by
a number of criteria that mirror a joint-destructive inflam-
matory process, it is a very heterogeneous disease in terms
of phenotype. The genetic heterogeneity of this disease is
most likely to be even more pronounced. In other words,
there are many different pathways that lead to rheumatoid
arthritis. Some of these lead to the same type of pathology,
whereas others produce slightly different variants of the
syndrome we call rheumatoid arthritis.
This variability is reflected in the described animal models
for rheumatoid arthritis. Although no model can accurately
reflect every aspect of such a heterogeneous disease, each
model may represent different pathogenic aspects of rele-
vance (Table 1). Mathis, Benoist and coworkers [1] have
recently described a new model for rheumatoid arthritis.
They first discovered that a T-cell receptor transgene, when
bred into mice expressing the major histocompatibility
complex (MHC) class II molecule Ag7, led to severe arthritis
with high penetrance. The transgenic T cells were specifi-
cally activated in response to an unknown, ubiquitously
expressed self-peptide in context with the Ag7 molecule. 
This group has now reported that this disease is caused by
antigen-specific immunoglobulin G (IgG) antibodies [2].
Transfer of serum or purified serum IgG antibodies from
the T-cell receptor transgenic mice into wild-type mice
resulted in the onset of arthritis as early as 24 hours after
transfer. The IgG-induced disease had some similar charac-
teristics to the spontaneously occurring arthritis in the
T-cell receptor transgenic mice, but differed in that it was
transient and the healing process did not result in the defor-
mation of joints. In contrast, in the T-cell receptor trans-
genic mouse, which has sustained levels of arthritogenic
antibodies, the healing response includes extensive new
bone formation leading to remodelling and deformation of
the joints that is not typical for rheumatoid arthritis. A more
detailed comparison of the IgG-induced model with earlier
established models for rheumatoid arthritis points to a
number of important similarities and differences.
This IgG-induced disease has several similarities with
various rheumatoid arthritis models induced by cartilage
proteins, for example collagen-induced arthritis, because
the arthritis is dependent on both T and B cells and tran-
sient arthritis can be induced with IgG self-reactive anti-
bodies or autoantibodies (reviewed in [3]). In fact, the
kinetics and pathology of the described IgG-mediated
arthritis is indistinguishable from anti-type II collagen
antibody-mediated arthritis. In addition, unlike rheuma-
toid arthritis but like collagen-induced arthritis, there is a
paucity of lymphocytes in joints. The main difference
between IgG-induced disease and collagen-induced
arthritis, however, is the apparent lack of cartilage-specific
immunity in IgG-induced arthritis. The arthritogenic IgG
antibodies recognise an antigen that is ubiquitously
expressed and not specific to cartilage. It remains an
important possibility that the ubiquitously expressed
protein is exposed in the joints as a neo-epitope — that is,
it is expressed by traumatised, stressed or apoptotic cells
in peripheral joints, and then released to form precipitat-
ing immune complexes that trigger the inflammation. A
similar mechanism may occur in the classical antigen-
induced arthritis model, in which arthritis occurs following
the injection of bovine serum albumin into the joints of
mice that have previously been immunized with the same
foreign protein. 
A comparison with other spontaneously occurring arthritis
models, such as mice overexpressing tumour necrosis
factor α [4] or the spontaneously occurring arthritis in
stressed mice [5] reveals several histopathological similari-
ties, such as the extensive remodelling of the joints. In
both of these spontaneously occurring models, however,
the immune system seems to play no role. Nevertheless,
the model in stressed mice is of general importance
because it seems to reflect a common pathway in response
to trauma or stress that, in most mouse strains, and most
likely also in humans, leads to deformation and healing of
tendon insertions (enthesopathy). In certain mouse
strains, this can be severe and can be mistaken macroscop-
ically for collagen-induced arthritis. Interestingly, a similar
form of enthesopathy can be induced in mice given an
overdose of vitamin A [6]. Thus, the activation of a ubiqui-
tously expressed protein, such as a hormonal receptor,
could also trigger a pathway leading to arthritis.
A comparison of IgG-induced arthritis with various adju-
vant-induced arthritis models, such as the pristane-
induced arthritis in rats [7], is of interest because these
models share the lack of arthritogenic autoimmune
response to cartilage proteins. There is therefore not a
straightforward explanation for the joint predilection in
either model. It has not yet been possible, however, to
transfer adjuvant-induced arthritis with serum and, in this
case, T cells seem to represent the only critical cell type
that contains immune specificity. There are two princi-
pally different ways for adjuvants to induce arthritis —
one is the triggering of innate immunity towards bacterial
cell-wall components and the other is the solubilisation in
cell membranes of the oil component used in adjuvants.
Both of these processes trigger a more or less joint-specific
inflammatory response that can develop into a chronic
disease course with extensive similarities to rheumatoid
arthritis. The chronic disease course is driven by a differ-
ent set of genes from those controlling the onset of arthri-
tis and may involve other mechanisms such as
cartilage-reactive T cells or pathogenic autoantibodies [7].
There is a pronounced activation of the acute-phase
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Table 1
The variety of different arthritic diseases in man and animals.
Synovitis* Bone and cartilage Enthesopathy and new Degeneration Rheumatoid 
erosions bone formation† of cartilage factors
Human disease:
Rheumatoid arthritis +++ +++ ± + ±
Osteoarthritis ± – ++ +++ –
Psoriasis arthritis ++ +/± +++ + –
Ankylosing spondylitis ++ ± +++ + –
Animal models:
Collagen-induced arthritis in mice +++ +++ +/± + + (IgG)
Anti-collagen II IgG transfer +++ ± – – ?
Pristane-induced arthritis in rats +++ +++ +/± + + (IgM)
Spontaneous arthritis in mice ± ± +++ – –
TNFα-induced arthritis in mice + +++ + +++ +
T-cell receptor transgenic mice +++ ++ +++ + –
IgG-mediated arthritis by transfer to mice +++ ± – – ?
An estimate of the intensity of the pathological process is graded from normal (–), minor changes (+), moderate changes (++), and severe changes
(+++). A slash indicates variability in different animals/individuals or observations. *Inflammation of the joint capsule. †Disease process in the
insertion area of tendons or ligaments usually leading to the formation of new cartilage and bone.
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response and a polyclonal B-cell activation, but the
autoantibody specificity and the pathogenic role has not
been fully elucidated. 
Taken together, the various animal models reflect differ-
ent parts of the pathology seen in rheumatoid arthritis and
several of them will be useful for elucidating the different
pathways. So, are there any specific events in rheumatoid
arthritis on which the new model could shed some light?
Despite the phenotypic and genetic heterogeneity of
rheumatoid arthritis, there are several phenomena that sur-
prisingly are shared by most rheumatoid arthritis patients. 
One commonality is the association of arthritis severity
and chronicity with certain MHC class II alleles. Another
is the contraction of the T-cell repertoire leading to a few
clonotypes that possibly reflects positive selection of T-
cell autoreactivity. A third phenomenon is the occurrence
of certain autoantibody reactivities in sera. It has recently
been demonstrated that autoantibodies preferentially
occurring in rheumatoid arthritis are not only specific for
immunoglobulin Fc (rheumatoid factors) and type II colla-
gen but also for a series of different more or less well-
defined autoantigens such as the A2 protein of the
heterogeneous nuclear ribonucleoprotein complex, the SA
protein and various citrullinated proteins [8,9]. Although
these reactivities are most likely involved at a secondary
level in the disease process, it would be interesting to
investigate whether there is a correlation between the
reactivities of the presently described pathogenic IgG
antibodies and these autoantibodies. In fact, the induction
of autoantibodies as a secondary effect may be important
not only for sustaining arthritis but also for development
of systemic manifestations, such as inflammation of serous
membranes (serositis) and blood vessels (vasculitis). The
observation that the reported T-cell receptor transgenic
mice did not only develop arthritis but also serositis could
be of further interest.
At this stage, therefore, the new model has raised more
questions than answers and the key factor will be its
applicability for further analysis of the pathogenic mecha-
nisms of rheumatoid arthritis. In this respect, this model
has some clear advantages. It should be possible to isolate
the autoantigenic peptide recognised by the transgenic T
cells, as well as the epitope(s) recognised by the patho-
genic antibodies. This might be a valuable tool to investi-
gate the link between the apparent recognition of a
ubiquitously expressed pathogen and an organ-specific
inflammatory attack. The most important contribution
might be, however, that the model reveals a new pathway
that can be investigated in detail by genetic techniques
and can be compared with other pathways used in differ-
ent models for rheumatoid arthritis. The antibody-medi-
ated induction of arthritis occurs rapidly with high
penetrance and is most likely controlled by a specific set
of genes that will be both similar to and different from
other animal models for rheumatoid arthritis. 
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